Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes?:A prospective, double-blind, randomised, placebo-controlled study by Brown, Alexander J. M. et al.
                                                              
University of Dundee
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2
diabetes?
Brown, Alexander; Lang, Chim; McCrimmon, Rory; Struthers, Allan
Published in:
BMC Cardiovascular Disorders
DOI:
10.1186/s12872-017-0663-6
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Brown, A. J. M., Lang, C., McCrimmon, R., & Struthers, A. (2017). Does dapagliflozin regress left ventricular
hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
BMC Cardiovascular Disorders, 17, 1-12. [229]. DOI: 10.1186/s12872-017-0663-6
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
STUDY PROTOCOL Open Access
Does dapagliflozin regress left ventricular
hypertrophy in patients with type 2
diabetes? A prospective, double-blind,
randomised, placebo-controlled study
Alexander J.M. Brown1, Chim Lang2, Rory McCrimmon3 and Allan Struthers4*
Abstract
Background: Patients with diabetes have a two to fourfold increased risk for development of and death from
cardiovascular disease [CVD]. The current oral hypoglycaemic agents result in limited reduction in this cardiovascular
risk. Sodium glucose linked co-transporter type 2 [SGLT2] inhibitors are a relatively new class of antidiabetic agent that
have been shown to have potential cardiovascular benefits. In support of this, the EMPA-REG trial showed a striking
38% and 35% reduction in cardiovascular mortality and heart failure [HF] hospitalisation respectively. The exact
mechanism (s) responsible for these effects remain (s) unclear. One potential mechanism is regression of Left
ventricular hypertrophy (LVH).
Methods: The DAPA-LVH trial is a prospective, double-blind, randomised, placebo-controlled ‘proof of concept’
single-centre study that has been ongoing since January 2017. It is designed specifically to assess whether the
SGLT2 inhibitor dapagliflozin regresses left ventricular [LV] mass in patients with diabetes and left ventricular
hypertrophy [LVH]. We are utilising cardiac and abdominal magnetic resonance imaging [MRI] and ambulatory
blood pressure monitoring to quantify the cardiovascular and systemic effects of dapagliflozin 10 mg once daily
against standard care over a 1 year observation period. The primary endpoint is to detect the changes in LV mass. The
secondary outcomes are to assess the changes in, LV volumes, blood pressure, weight, visceral and subcutaneous fat.
Discussion: This trial will be able to determine if SGLT2 inhibitor therapy reduces LV mass in patient with diabetes
and LVH thereby strengthening their position as oral hypoglycaemic agents with cardioprotective benefits.
Trial registration: Clinical Trials.gov: NCT02956811. Registered November 2016.
Keywords: Diabetes, SGLT2 inhibitor, Left ventricular hypertrophy, Mechanistic trial, Cardiac MRI
Background
Patients with type 2 diabetes mellitus [T2DM] have
double the risk of cardiovascular death [CVD] compared
with patients without T2DM [1, 2]. Hyperglycaemia it-
self contributes to both the pathogenesis of atheroscle-
rosis and heart failure [3]. While intensive glucose
control reduces the risk of microvascular complications
it appears to be insufficient to reduce cardiovascular
[CV] events [4]. Three large randomized controlled trials
[RCTs] ADVANCE, ACCORD and VADT failed to dem-
onstrate any significant effect on macrovascular events
of more intensive glycaemic control in patients with
longstanding T2DM when compared with standard
medical care [5–7].
The EMPA-REG OUTCOME trial was a landmark trial
as it demonstrated for the first time that a glucose lowe-
ring agent could reduce CV events [8]. It was a multicen-
tre, randomised, double blind, placebo-controlled trial
performed in 7020 patients with T2DM at high cardio-
vascular risk comparing the SGLT2 inhibitor empagliflo-
zin to placebo. In the empagliflozin group there were
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significantly lower rates of death from cardiovascular
causes and heart failure hospitalisations, by 38 and 35%
respectively. The exact mechanisms responsible for these
effects remains unclear.
Left ventricular hypertrophy
One potential mechanism is regression of left ventricular
hypertrophy [LVH]. Left ventricular hypertrophy is
thought to be present in up to 70% of patients with
T2DM [9] It is a strong independent predictor of cardio-
vascular deaths and events and is even worse than triple
vessel coronary disease [10, 11]. The reason why LVH is
so adverse is because it predates so many different car-
diovascular events i.e. LVH is intrinsically arrhyth-
mogenic and causes sudden death, it impedes left
ventricular [LV] filling and leads to diastolic heart fai-
lure, it reduces coronary perfusion reserve and causes is-
chaemia and it causes left atrial enlargement leading to
atrial fibrillation [AF], and cardio-embolic strokes [12].
How does one cause regression of LVH? Controlling
blood pressure [BP] and using a drug that blocks the
renin-angiotensin system [RAS] are the standard ap-
proaches to the management of LVH but this approach is
only partially effective since 44% of all patients with T2DM
are normotensive patients with LVH [9]. Thus normoten-
sive LVH is very common [9, 13]. Indeed, BP only contrib-
utes 25% to the variability in LV mass seen in a population
[14]. Despite a “normal” BP, normotensive LVH is just as
risky as is hypertensive LVH [15]. Nevertheless, we do
know that regressing LVH irrespective of BP changes is an
effective way to reduce the incidence of all major cardio-
vascular [CV] events including specifically sudden deaths,
heart failure hospitalisations, new onset AF and strokes
[16–23]. The LIFE trial provides conclusive proof that in
diabetes, LVH regression per se reduces future cardio-
vascular events [by 24%], reduces CV deaths [by 37%] and
reduces total deaths [by 41%] irrespective of BP [24].
Since controlling BP and using an angiotensin en-
zyme inhibitor or angiotensin receptor blocker is only
partially effective at regressing LVH, we now need add-
itional ways of regressing LVH. Insulin resistance is an-
other mediator of LVH. The literature is awash with
observational studies linking insulin resistance to LVH.
The large studies are mostly positive which includes the
Framingham Study, the Whitehall trial, the Strong Heart
trial and the Women’s Health Initiative trial while Hyper-
GEN is the one large negative trial [25–29]. Therefore, it
is likely that glycaemia contributes to LVH. However,
there is little evidence to date that glycaemic control alone
affects the risk of CV events and thus key ancillary
properties of each anti-glycaemic drug will be necessary
to deliver the CV benefits we so badly need in diabetes
[4, 30, 31]. A separate albeit related factor associated
with LVH is also obesity [25, 32, 33].
Sodium glucose linked co-transporter2 [SGLT2] inhibitors
and their potential to regress LVH
In this study, we hypothesize that SGLT 2 inhibitors may
be able to lead to LVH regression. Firstly, SGLT2 inhi-
bitors employ a novel mechanism to lower blood glucose
by enhancing urinary glucose excretion by competitively
blocking the sodium glucose linked co-transporters in the
proximal renal tubules, thus preventing the reabsorption
of filtered glucose and sodium, resulting in glycosuria and
natriuresis [34, 35]. This is in contrast with other anti-
diabetic medications which focus on restoring β-cell acti-
vity, insulin sensitivity and tissue glucose uptake to reduce
plasma glucose levels. Accordingly, SGLT2 inhibitors are
expected to maintain their potency as beta cell function
declines with disease progression. Secondly, the glycosuric
effects of SGLT2 inhibitors result in around 240-400 kcal/
day loss through the urinary tract [36]. This calorific loss
results in an average weight loss of around 2-3 kg that
could help lead to LVH regression [37]. Finally, the natri-
uretic effect and subsequent osmotic diuresis could also
be significant in patients with cardiovascular disease. This
diuretic effect should reduce preload on the heart. The
SGLT2 inhibitors lower blood pressure by 7-10 mmHg,
reduce arterial stiffness and afterload [38–40].
In summary, SGLT2 inhibitors may improve cardiac
structure because they appear to reduce the four main
causes of LVH: glycaemia/insulin resistance, weight, pre-
load and afterload [blood pressure] [41]. Our hypothesis
is that dapagliflozin will regress LVH in normotensive
patients with T2DM. If so, this could be a large part of
explaining why such drugs reduce CV events in the
EMPA-REG OUTCOME trial.
The issue of how SGLT2 Inhibitors reduces CV events
in diabetes is a hot topic following EMPAREG OUT-
COME. A large ongoing trial [DECLARE – TIMI 58] is
also in progress assessing the effect of Dapagliflozin on
CV events. If DECLARE-TIMI 58 shows clearly that
dapagliflozin reduces CV events, then our trial if positive
will have revealed a possible contributing mechanism to
the reduced CV events i.e. LVH regression.
Methods
Study design
The DAPA-LVH trial is a prospective, double-blind,
randomised, placebo-controlled ‘proof of concept’ single-
centre study conducted in NHS Tayside, Scotland de-
signed to evaluate the efficacy of 12 months of the
SGLT2 inhibitor dapagliflozin compared to placebo on
left ventricular hypertrophy [LVH] in 64 normotensive
participants with diabetes identified to have LVH. A re-
cruitment window of 1.5 years from December 2016 has
been set. Participants will be enrolled in this trial for a
period of 12–13 months, [Fig. 1]. Therefore, the overall
trial end date will be May 2019.
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At the screening visit an initial medical history and
clinical examination will be performed following in-
formed consent. Participants will have an electrocardio-
gram performed and bloods taken for safety analysis.
Vital signs including blood pressure will be recorded to
confirm eligibility prior to enrolment. Blood pressure
will be taken using an Omron M10-IT blood pressure
monitor and eligible patients will have an office blood
pressure of 145/90 mmHg averaged over three readings.
Patients who require optimisation of their blood pres-
sure will do so but will have to be stable on their current
antihypertensive medications for 3 months prior to en-
rolment. Patients with borderline office blood pressure
will undergo ambulatory blood pressure measurement
(AMBP) This will be performed using a Spacelab 90,217
ambulatory blood pressure monitor. Inclusion will be pos-
sible with a 24 h mean blood pressure < 140/85 mmHg.
Participants will also be screened for echocardiographic
evidence of left ventricular hypertrophy [LVH] by the
standard American Society of Echocardiology [ASE]
criteria. This will be performed using a Philips Epiq 7 ma-
chine by a fully trained operator. Eligible participants
identified to have LVH on echocardiography will be
recruited. The full inclusion criteria are as listed below.
Recruited patients will return for a cardiac magnetic
resonance imaging [CMRI] at the Clinical Research
Centre, Ninewells Hospital, Dundee, within 3 weeks of
the planned baseline [randomisation] visit. At the ran-
domisation visit participants will have vital signs, body
mass index, waist circumference and waist to hip ratio
recorded. Participants will also be asked to undergo 24 h
ambulatory BP monitoring using a Spacelab 90,217 am-
bulatory monitor. Examinations with greater than 50%
successful readings will be deemed an acceptable exam.
Bloods for safety analysis and research purposes [BNP,
FIRI and Uric acid] will also be taken. During the visit,
participants will also be randomly be assigned to either
dapagliflozin 10 mg or matching placebo. The first dose
Fig. 1 Study design flowchart. SDRN Scottish Diabetes Research Network; SPRN Scottish Primary Research Network; MRI Magnetic Resonance
Imaging; BP Blood Pressure; BMI: Body Mass Index
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will be administered during this visit and participants will
be educated on the symptoms of both hypoglycaemia and
diabetic ketoacidosis and given written instructions of
how to manage it if either event occurs.
To reduce the likelihood of hypoglycaemia in partici-
pants taking insulin, participants who are already on in-
sulin at time of recruitment will have their total daily
dose of insulin reduced by 10% on the day they are ran-
domised. Further dose titration will be done by the study
team or GP based on the participant’s symptoms, home
and laboratory-based blood sugar levels. Down-titration
of therapy will be done in a stepwise manner starting
with insulin. Other anti-diabetic agents will only be
down-titrated once insulin has been discontinued.
In order to make the two groups comparable, a target
HbA1c of ≤ 53 mmol/mol will be set for all participants.
New onset diabetic patients will not be included in this
study as SGLT2 inhibitors are currently only licensed as
second line therapy. We will therefore be comparing a
dapagliflozin [mostly as a second drug after metformin]
based group against a conventionally treated group but
without a SLGT2 inhibitor.
This will ensure that any difference in LV mass be-
tween groups is because dapagliflozin and all its ancillary
cardiac properties and not because the two groups dif-
fered in glycaemic control.
With regards to BP, the main criteria will be that the
baseline office BP is < 145/90 mmHg. However, the in-
vestigator will have clinical discretion to change anti-
hypertensive drugs during the trial for safety reasons,
under two circumstances. Firstly, if the systolic BP rises
to above 140 mmHg on 2 consecutive visits during the
trial then the participant can be started on extra anti-
hypertensive drugs to re-achieve a systolic BP of <
145 mmHg. Secondly, if the participant suffers from
dizziness and/or their systolic BP has fallen either by ≥
25 mmHg or to an absolute level of ≤ 110 mmHg, then
the attending physician can reduce or stop one of their
antihypertensive drugs. These criteria serve two func-
tions: firstly, to copy normal clinical practice and sec-
ondly to maintain participant safety.
Participants will return for three visits throughout the
year to have safety and research bloods taken and to
have vital signs, BMI, waist to hip ratio and waist cir-
cumference recorded. They will also be assessed for ad-
verse events and to alter diabetic/antihypertensive
therapy [if applicable].
The biomarker samples will be centrifuged and dec-
anted into an aliquot which will be stored at -80 °C. Uric
acid will be analysed with an elisa method using
SIGMA-ALDRICH assay, UK. BNP will be measured by
a MULTI-ARRAY system. The kit is from MESO SCALE
DISCOVERY, USA. FIRI will be analysed with an elisa
method using an ALPCO assay UK.
At the end of the 1 year study period, participants will
return for repeated assessment of vital signs, BMI, waist
circumference and waist to hip ratio, ambulatory blood
pressure, echocardiography and CMRI. These values will
be compared with their baseline tests to determine if
any significant change has occurred with each of the two
arms of the study populations. [See Table 1 for an over-
view of all visits scheduled for the trial].
Study population
Diabetic patients with LVH will be identified for this
study and all potential participants who meet the follo-
wing criteria will be eligible for the trial:
Inclusion criteria:
 Diagnosed with type 2 diabetes mellitus based on
the current American Diabetes Association guidelines.
 Aged 18–80 years
 Body Mass Index ≥ 23 kg/m2
 HbA1c 48-85 mmol/mol [last known result within
in the previous 6 months]
 BP < 145/90 mmHg. Office BP at screening visit will
be used however if this is above the inclusion criteria
then the 24 h recording at screening visit will be used
to confirm that in the opinion of the PI the BP is
adequately controlled.
 Echocardiographic LV hypertrophy (defined as either
an LV mass index of >115 g/m2 for men and > 95 g/m2
for women indexed to body surface area or > 48 g/m2.7
or 44 g/m2.7 when indexed to height2.7)
 Women of childbearing potential* [WoCBP] must
agree to take precautions to avoid pregnancy
throughout the trial and for 4 weeks after intake of
the last dose
Exclusion criteria:
 Any condition that in the opinion of the investigator
may render the participant unable to complete the
trial including non CV disease [e.g. active malignancy].
 Participants with type 1 diabetes mellitus
 Participants who have previously had an episode of
diabetic ketoacidosis.
 Serum Potassium or Sodium results outwith the
normal range
 Diagnosis of clinical heart failure
 History of human immunodeficiency virus
 LV systolic dysfunction [LVEF < 45%] [last known
result within in the previous 6 months]
 eGFR < 60 ml/min/1.73m2 [last known result within
in the previous month] assessed using an
abbreviated Modification of Diet in Renal Disease
(MDRD) equation and indexed to 1.73m2.
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 Known liver function tests > 3 times upper limit of
normal [based on last measures and documented
laboratory measurement in the previous 6 months]
 Body weight > 150Kg [unable to fit into a MRI
scanner]
 Contraindications to MRI [e.g. claustrophobia, metal
implants, penetrative eye injury or exposure to metal
fragments in eye requiring medical attention]
 Past or current treatment with any SGLT2 inhibitor
 Allergy to any SGLT2 inhibitor or lactose or
galactose intolerance
 Current treatment with loop diuretic
 Currently receiving long term [> 30 consecutive
days] treatment with an oral steroid
 Pregnant or breast feeding participants
 Involvement in the planning and/or conduct of the
trial [applies to Astra Zeneca or representative staff
and/or staff at the trial site].
 Participation in another interventional study [other
than observational trials and registries] within
30 days before visit 1.
 Individuals considered at risk for poor protocol or
medication compliance
Randomisation and treatment allocation
After successful screening for eligibility and safety, par-
ticipants will be randomised to either dapagliflozin
10 mg or matching placebo [identical tablet containing
lactose] in a double blind fashion. The double blind
medication [dapagliflozin or placebo] will be prepared
Table 1 Overview of all the study visits in the DAPALVH trial
Visit 1 Screening 2 Baselinea 3 follow-upa 4 Follow-upa 5 Follow-upa 6 Last visita
Timeline - weeks 0 to − 4 0 Within 4 weeks
of screening visit
4b [+/− 1 week] 17 [+/− 4 weeks] 34 [+/− 4 weeks] 52 [+/− 4 weeks]
Informed Consent X
Medical History X
Demographics X
Concomitant Medications X X X X X X
Physical Examination X
Height & weight X
BP & P X X X X X X
Temperature X
ECG X
Echoc X X
Safety Bloodsd X X X X X X
Inclusion/Exclusion X
Pregnancy Testing if applicablee X X X X X X
Research Blood Sample f X X X X X
Genetic blood sample X
24 h BP X X
Cardiac & abdominal MRIg X X
Waist & hip measurement X X X X X
Adjustment of diabetes medication X X X X
Adjustment of anti-hypertensive medication X X X X
Record Adverse Events X X X X X
Randomisation X
Dispense Trial Drugs Xh X X X
Return trial drugs X X X X
aParticipants will be fasted for these visits
bAt least 3 weeks after commencing study medication
cIf a participant has had a clinical echo done within the previous 6 months the results from this will be used for assessing eligibility, otherwise an echo
will be performed at the screening visit
dU&E, FBC, LFT, cholesterol, HDL-cholesterol
eSee section 7.2
fHbA1c, FIRI, BNP, glucose, uric acid. A sample to be held for future research will be taken at the last visit
gThe MRI scan may be performed ± 3 weeks from the baseline visit and may therefore require a separate visit
hIf the participant as not yet had their MRI scan they will be asked not to start their study medication until they have had their scan. Their Visit 3 will
be delayed until the patient has had at least 3 weeks of study medication
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and packaged by AstraZeneca and labelled by our onsite
clinical trials pharmaceutical pharmacy. Randomisation
will be carried out via our Tayside Randomisation Sys-
tem [TRuST], a Good Clinical Practice [GCP] compliant
web-based system run by the Tayside Clinical Trials Unit
[TCTU], to preserve allocation concealment. This will
securely backup both the randomisation seed and the
randomisation allocation and have it available in the
onsite 24 h emergency unblinding facility.
Once randomised, the participant will continue to take
the trial medication once daily for 1 year, if tolerated.
Compliance will be checked and documented, by the
dispensing pharmacy, using tablet counts at each visit. If
non-compliant, they will be encouraged to become com-
pliant. If study drug needs to be stopped due to intoler-
ance or adverse events, they will remain in the study in
order to do an “intention to treat” analysis.
Study outcomes
Primary objective and outcome
The primary outcome is to determine if dapagliflozin re-
duces left ventricular [LV] mass in patients with type 2
diabetes and LV hypertrophy when compared to
placebo.
Secondary outcomes
 To determine if dapagliflozin has any effect on LV
diastolic function.
 To determine if as expected dapagliflozin reduces
blood pressure [BP]
 To assess the effect of dapagliflozin on left ventricular
diastolic function and global longitudinal strain
 To determine if as expected dapagliflozin reduces
body weight
 To determine if dapagliflozin reduces visceral fat mass
 To determine if as expected dapagliflozin reduces
HbA1C.
 To determine the effect of dapagliflozin on B-type
natriuretic peptide [BNP], Uric acid and Fasting
Insulin Resistance Index [FIRI]
 To assess the tolerability of dapagliflozin in this
patient group
Sample size and power calculations
For the primary outcome of LV mass regression using
cardiac MRI, we have powered this study for an absolute
change in LV mass based on previous studies that we
have conducted in our unit. In our recently published
study of LVH regression using allopurinol in participants
with ischaemic heart disease [41], we found that allopur-
inol significantly reduced LV mass by − 5·2 ± 5·8 g com-
pared to placebo − 1·3 ± 4·5 g [p < 0·007]. In per-cent
terms, this degree of LVH regression is the same as seen
between the two arms of the echo sub-study of the LIFE
study where CV events were also different between
groups. For an 80% power at a 5% significance level [α
= 0·05], to detect a similar change in LV mass, we will
require 29 subjects per group. Both our previous stud-
ies have shown a 10% dropout rate. Therefore, account-
ing for this, we will require a total of 64 participants
[32 per group]. The 10% dropout rate is standard for
such studies and includes those who died and those
who withdraw consent.
Cardiac MRI protocol
Baseline and repeat Cardiac magnetic resonance imaging
[CMRI] examinations at baseline visit [+/− 3 weeks] and
after the final 12 month [+/− 4 weeks] visit will be per-
formed on a 3 T Magnetrom Trio scanner [Siemens,
Erlangen, Germany] using body array and spine matrix
radiofrequency coils.. Short axis images from the atrio-
ventricular ring to the LV apex will be acquired using a
2D ECG-gated breath hold segmented SSFP cine se-
quence with retrospective gating. Quantitative measure-
ment of LV mass, ejection fraction (EF), end-diastolic
volume (EDV), end-systolic volume (ESV) and stroke
volume (SV) will be derived by region of interest con-
tours placed around endocardial and epicardial LV bor-
ders at end systole and end diastole.
Transmitral flow and the isovolumetric relaxation time
will be assessed using through plane phase contrast im-
ages with electrocardiographic synchronisation.
At the same time of the CMRI visceral and subcutane-
ous abdominal fat mass will be assessed. For measurement
of subcutaneous adipose tissue (SCAT) and visceral adi-
pose tissue (VAT) two successive axial 3D DIXON volume
interpolated breath hold examination sequences will be
acquired. These sequences will cover an anatomical area
from the diaphragm to the pelvic floor, with a slice thick-
ness of 3 mm and up to 88 slices (dependent on patient
size) collected within a single 3D block.
For image analysis the ‘fat only’ DIXON MR images
will be segmented using Analyze (Mayo Clinic) software,
and the SCAT and VAT compartments are defined using
a signal intensity threshold method with manual correc-
tion where required. Epicardial fat structures and fat as-
sociated with the vertebrae will both be omitted from
the final calculated volumes.
From a single MRI slice at the L2-L3 intervertebral
level. This single observer will analyse all the scans. Ana-
lysis will be performed offline [Argus Software, Siemens]
by a single blinded observer.
The reproducibility of all parameters using MRI will
be derived by this observer. A test-retest intra-observer
co-efficient of variation of 2.0% is usual in this depart-
ment’s past MRI studies. Should the scanner become un-
available for a prolonged period of time during the study
an alternative scanner will be used. MRI methods will be
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adapted as appropriate to ensure optimal study results
can be obtained.
Discussion
SGLT2 inhibitors including dapagliflozin improve sys-
temic glucose metabolism, lower blood pressure and
lower body weight, thus they ameliorate the metabolic
and haemodynamic risk factors heavily implicated in
causing LVH. In this study, we propose that the SGLT2
inhibitors may be particularly suitable at regressing
LVH. This effect might ultimately explain the reduced
CV events seen so far in one large outcome trial with
these drugs [Fig. 2].
The primary haemodynamic effect of SGLT2 inhibitors
is an osmotic diuresis. Patients treated with dapagliflozin
produce approximately 375mls of extra urine per day
[36]. Several trials have shown that SGLT2 inhibitors
lead to a reduction in systolic BP in a range of 3-5 mmHg
and ~ 2-3 mmHg in diastolic BP [37]. This will be fur-
ther assessed in our trial with ambulatory blood pressure
recordings at randomisation and upon completion of the
trial. The reason for the observed BP reduction with
SGLT2 inhibition is not completely understood but is
likely secondary to several different things including the
modest diuretic effect, mild natriuresis and weight re-
duction [39, 42]. Data from a mechanistic trial has also
demonstrated that empagliflozin reduced arterial stiffness
in patients with type 1 diabetes mellitus [43]. These
effects on intravascular volume and blood pressure will
result in reduced preload and afterload respectively,
thereby facilitating a reduction in intra-cardiac pressure
and thereby an improvement in cardiac structure [24, 44].
Indeed following EMPA-REG Outcome trial there has
been a lot of interest in the effects of SGLT2 inhi-
bition on cardiac structure with a number of ongoing
trials looking into the effects in patients with both
diastolic and systolic heart failure in addition to car-
diovascular outcomes [Tables 2, 3, and 4].
Dapagliflozin is known to produce clinically meaning-
ful reductions in HbA1c. [45] Studies have also shown
that treatment with SGLT2 inhibitors improves insulin
sensitivity as measured by peripheral glucose uptake
[46, 47]. One such study showed that insulin mediated
tissue glucose disposal increased by around 18% with
only 2 weeks of dapagliflozin therapy [47]. Insulin re-
sistance and hyperinsulinaemia have been associated
with increased atherosclerosis risk and left ventricular
hypertrophy [25–29, 48].
Other metabolic effects of the SGLT2 inhibitors in-
clude weight loss. With selective SGLT2 inhibition urin-
ary glucose is increased resulting in a negative energy
balance and subsequent weight loss [36]. A 24 week
Fig. 2 DAPA LVH trial hypothesis. The above figure explains the hypothesis of the DAPALVH trial where reduction in preload and afterload,
weight and insulin resistance will all contribute to regression of left ventricular hypertrophy. This will be measured by cardiac MRI. BNP: B Type
Natriuretic Peptide; BP: Blood Pressure; EDV: End Diastolic Volume; FIRI: Fasting Insulin Resistance Index; HBA1C: Glycosylated Haemoglobin; IVRT:
Isovolumetric Relaxation Time; LA: Left Atrial; LV: Left Ventricular; LVEF: Left Ventricular Ejection Fraction; LVH: Left Ventricular Hypertrophy; MRI:
Magnetic Resonance Imaging
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study comparing dapagliflozin to placebo showed a 2.5–
3.5 kg weight reduction as a result of the calorific loss
produced by glycosuria [49]. This is a finding throughout
the SGLT2 class [37]. Of potential greater interest is
how they change visceral fat mass as this is associated
with an increased risk of T2DM and increased risk of
CVD and overall mortality [50]. Indeed all the three cur-
rently available SGLT2 inhibitors when compared to gli-
mepiride in dedicated body composition studies have
shown that the majority of weight loss associated with
SGLT2 inhibition was due to a reduction in visceral fat
or subcutaneous fat [45, 51, 52]. Accordingly, we have
chosen to also measure visceral and subcutaneous fat
mass as a secondary outcome of the DAPA-LVH.
Given these metabolic and haemodynamic effects our
hypothesis is that we will see a reduction in left ven-
tricular mass. Indeed, pre-clinical work has shown that
SGLT2 inhibitors are capable of reducing LV mass in a
rat model with progressive HF [53]. We have therefore
selected CMRI measurements of LV mass as our primary
outcome measures for the DAPALVH Trial. By ensuring
the trial is adequately powered we will determine if
treatment with an SGLT2 inhibitor is able to reduce LV
mass in diabetic patients with LVH.
Table 2 Ongoing trials assessing the use of SGLT2 inhibitors in patients with systolic heart failure
SGLT2 Inhibitor Trial Name; Clinical Trial Identifier Primary Outcome measure Patient Populationa Final Results
Empagliflozin Empagliflozin Impact on Haemodynamics
in Patients with Diabetes and Heart Failure
[EMBRACE-HF]. [54]
NCT03030222
Change in pulmonary artery
diastolic pressure
N = 60
10 mg vs placebo
Either LVEF 40% or > 40%
NHYA II-IV
HbA1c ≥ 6.5% and ≤ 11%
GFR > 30 ml/min
June 2018
Empagliflozin SGLT2 Inhibition in Diabetic Patients With
Heart Failure with Reduced Ejection
Fraction [55]
NCT02862067
SGLT2 inhibition effects on
cardiorespiratory fitness
N = 31
10 mg/25 mg standard care
LVEF ≤ 50% [in maximum
tolerated HF therapy
HbA1c 7–10%
Age ≥ 18 years
GFR > 45 ml/min
June 2018
Empagliflozin EMPagliflozin outcomE tRial in Patients
with chrOnic heaRt Failure with Reduced
Ejection Fraction [EMPEROR-Reduced] [56]
NCT03057977
Time to first event of adjudicated
CV death or adjudicated
hospitalisation for HF in patients
with HF with reduced ejection
fraction
N = 2850
LVEF ≥ 36to ≤ 40%:
NTproBNP ≥ 2500 pg/ml
LVEF ≥ 31% to ≤ 35%:
NT-proBNP ≥ 1000 pg/ml
If LVEF ≤ 30% NT-proBNP
≥ 600 pg/ml
Age > 18 years
GFR > 20 ml/min
June 2020
Dapagliflozin Dapagliflozin Effect on Symptoms and
Biomarkers in Diabetes Patients with Heart
Failure [DEFINE-HF] [57]
NCT02653482
Differences in the average reduction
of NTproBNP
Proportion of patient that achieve
a ≥ 5pts increase in heart failure
disease specific quality of life score
or a ≥ 20% decrease in NTproBNP
N = 250
10 mg vs placebo
LVEF ≤ 40/NHYA II-III
HbA1c 6.5–11.0%
Age 19–119 years
GFR > 45 ml/min
BNP ≥ 125 pg/ml and/or
NTproBNP ≥ 600 pg/ml
May 2017
Dapagliflozin Study to Evaluate the Effect of dapagliflozin
on the Incidence of Worsening Heart Failure
or Cardiovascular Death in Patients With
Chronic Heart Failure With Reduced Ejection
Fraction [Dapa-HF]. [58] NCT03036124
Time to first occurrence of the
composite: CV death or hospitalisation
for HF or urgent HF visit.
N = 4500
5/10 mg vs placebo
LVEF ≤ 40/NHYA II-IV
Age 18 to 130 years
GFR > 30 ml/min
NTproBNP ≥ 600 pg/ml
December 2019
Dapagliflozin Safety and Effectiveness of SGLT2 inhibitors in
Patients with Heart Failure and Diabetes
[REFORM] [59]
NCT02397421
Change in LV end systolic volume or
LV end diastolic volume as determined
by CMRI
N = 56
10 mg vs placebo.
LVEF < 50%/NYHA I-II
HbA1c > 6%
Age 18 to 75 years
GFR > 45 ml/min
August 2017
Canagliflozin A Randomised Active-Control Double-Blinded
Study to Evaluate the Treatment of Diabetes
in Patients with Systolic Heart Failure. [60]
NCT02920918
Change from baseline aerobic exercise
capacity
Change from baseline ventilator
efficiency
N = 88
LVEF ≤ 40%/NYHAII-III
HbA1C 6.5%–10%
Age ≥ 18 years
GFR >50 ml/min
November 2018
aEnrolment details correct at the time of writing as per ClinicalTrials.gov
BNP B Type Natriuretic Peptide, CMRI Cardiac Magnetic Resonance Imaging, ESKD End Stage Kidney Disease, GFR Glomerular Filtration Rate, HbA1C
Glycosylated Haemoglobin, HF Heart Failure, LV Left Ventricular, LVEF Left Ventricular Ejection Fraction, NTproBNP N Terminal pro brain natriuretic
peptide, NYHA New York Heart Association, SGLT2 Sodium Glucose Linked Co-Transporter2
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The EMPA-REG Outcomes trial revealed a reduction
in cardiovascular death and HF hospitalisations with the
use of empagliflozin in patients with T2DM. However,
it is unknown if these effects are seen throughout the
SGLT2 inhibitor class. Other cardiovascular outcome
trials such as DECLARE-TIMI 58 for dapagliflozin
and CANVAS for canagliflozin will reveal whether the
cardioprotective effects of SGLT2- inhibitor therapy is
seen across the drug class. As described above this
study will provide insights into the mechanism of the
Table 3 Ongoing Trials assessing the use of SGLT2 in patients with left ventricular hypertrophy or heart failure with preserved
ejection fraction
SGLT 2 Inhibitor Trial Name; Clinical Trial Identifier Primary Outcome Measure Patient Populationa Final Results
Empagliflozin Effects of Empagliflozin on Left
Diastolic Function Compared to
Usual Care in Type 2 Diabetics
[EmDia]. [61] NCT02932436
Difference in E/E’ ratio measured
by echocardiography
N = 264
10 mg vs placebo
Age 18–84 years
HbA1C ≥ 7–10% on
diabetic therapy or
≥ 7–9% diet controlled
GFR > 60 ml/min
October 2017
Empagliflozin SGLT2 Inhibition and Left Ventricular
Mass [EMPATROPHY] [62];
NCT 02728453
Change in ventricular mass assessed
using CMRI
N = 60
25 mg vs 2-4 mg Glimepiride
LVEF ≥ 45%
Age ≥ 40 and < 80 years
Office BP ≤ 150/95 mmHg
HbA1C 6.5–9%
GFR > 60 ml/min
April 2018
Empagliflozin Effects of Empagliflozin on Cardiac
Structure in Patients with Type 2
Diabetes [EMPA-HEART] [63]
NCT02998970
Left Ventricular Mass changes
measured by CMRI at 24 weeks
N = 90
10 mg vs placebo
LVEF > 30%
Age ≥ 40 and ≤ 80 years
HbA1C 6.5- ≤ 10%
GFR > 60 ml/min
June 2017
Dapagliflozin Effects of Dapagliflozin on Biomarkers,
Symptoms and Functional Status in
Patients With Type 2 Diabetes or
Pre-diabetes, and PRESERVED Ejection
Fraction; [64]
NCT030302235
Changes from baseline in NTproBNP N = 320
10 mg vs placebo
LVEF ≥ 45%
Age 19 to < 119 years
HbA1C ≥ 5.7 - < 11%
GFR < 30 ml/min
March 2019
Dapagliflozin Does Dapagliflozin Regress Left
Ventricular Hypertrophy in Patients with
Type 2 Diabetes; [65]
NCT02956911
Left Ventricular Mass changes measured
by CMRI at 52 weeks
N = 64
10 mg vs placebo
LVEF ≥ 45%
Age ≥ 18 and ≤ 75 years
HbA1C ≥ 7 - < 10%
GFR > 60 ml/min
May 2019
aEnrolment details correct at the time of writing as per ClinicalTrials.gov
CMRI Cardiac Magnetic Resonance Imaging, GFR Glomerular Filtration Rate, HbA1C Glycosylated Haemoglobin, HF Heart Failure, LV Left Ventricular, LVEF
Left Ventricular Ejection Fraction, NTproBNP N Terminal pro brain natriuretic peptide, NYHA New York Heart Association, SGLT2 Sodium Glucose
Linked Co-Transporter2
Table 4 Ongoing Cardiovascular Outcome Trials with SGLT2 inhibitors
SGLT2 Inhibitor Trial Name; Clinical Trial Identifier Primary Outcome Measure Patient Populationa Final Results
Dapagliflozin Dapagliflozin Effect on Cardiovascular
Events. [DECLARE TIMI 58];
[66] NCT 01730534
CV Death, non-fatal MI,
non-fatal ischaemic stroke
N = 17,276
10 mg vs placebo
HbA1C range not specified
Age ≥ 40 years
High CV risk
2019 [Estimated]
Canagliflozin Canagliflozin Cardiovascular Assessment
Study. CANVAS]; [67]
NCT 01032629
CV Death, non-fatal MI,
non-fatal ishaemic stroke
N = 4422
100 mg/300 mg vs placebo
HbA1C 7–10.5%
Age ≥ 30 years
High CV risk
June 2017
Canagliflozin Evaluation of the Effects of Canagliflozin
on Renal and Cardiovascular Outcomes in
Participants with Diabetic Nephropathy
[CREDENCE] [68];
NCT 02065791
Time to first occurrence of
an event in the primary
composite of endpoint of
ESKD, doubling of serum
creatinine, renal or CV death.
N = 4200
100 mg vs placebo
HbA1c 6.5–12%
Age > 30 years
GFR ≥ 30 to < 90 ml/min
June 2019
aEnrolment details correct at the time of writing as per ClinicalTrials.gov
ESKD End Stage Kidney Disease, GFR Glomerular Filtration Rate, HbA1C Glycosylated Haemoglobin, HF Heart Failure, LV Left Ventricular, LVEF Left
Ventricular Ejection Fraction, NYHA New York Heart Association, SGLT2 Sodium Glucose Linked Co-Transporter2
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positive cardiovascular effects conferred by SGLT2 inhibi-
tor therapy and may also help decide the course of future
research – should LVH be a favoured target?
Limitations
Firstly, this is a relatively small, single centre trial. The
use of CMRI though has allowed the power of the trial
to be preserved despite the small number of participants.
However, given the small numbers some differences ob-
served may still be the result of chance. Secondly, dia-
betes is a dynamic disease as a patient’s glycaemia
control may fluctuate and this may necessitate dose ad-
justments of anti-diabetic medications during the trial
which may confound the outcome. However, every
measure will be taken to ensure blinding of the investi-
gators is maintained and uniformity in the dose adjust-
ments made.
Conclusion
Historically much attention has focused on the preven-
tion and treatment of the microvascular complications
of diabetes. CVD however is still the main co-morbid
condition and primary contributor to mortality in pa-
tients with diabetes. Besides metformin therapeutic
options to optimise glycaemic control which reduce
cardiovascular risk are limited. Empagliflozin an SGLT2
inhibitor has been shown to produce significant reduc-
tions in cardiovascular mortality and hospitalisation with
heart failure [8]. We propose that SGLT2 inhibitors may
cause regression of LVH due to their ability to reduce
preload/afterload, weight and insulin resistance which
may account for their positive cardiovascular effects.
Upcoming major trials will establish if the effect seen
with empagliflozin is an SGLT2 class effect. If so, the
results of this study if positive will help us understand
the mechanisms of the cardioprotective effects of SGLT2
inhibitors and if positive further establish this group of
medications as anti-diabetic agents with the added value
of protecting the heart.
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